Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash from Operations: 2018-2025

Historic Cash from Operations for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to -$15.4 million.

  • Whitehawk Therapeutics' Cash from Operations rose 1.97% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$95.3 million, marking a year-over-year decrease of 75.93%. This contributed to the annual value of -$59.5 million for FY2024, which is 0.19% up from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Cash from Operations of -$15.4 million as of Q3 2025, which was up 70.96% from -$53.0 million recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Cash from Operations ranged from a high of $10.6 million in Q1 2021 and a low of -$53.0 million during Q2 2025.
  • In the last 3 years, Whitehawk Therapeutics' Cash from Operations had a median value of -$15.4 million in 2025 and averaged -$18.1 million.
  • Per our database at Business Quant, Whitehawk Therapeutics' Cash from Operations surged by 368.11% in 2021 and then crashed by 478.32% in 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Cash from Operations (Quarterly) stood at -$12.4 million in 2021, then climbed by 9.00% to -$11.3 million in 2022, then rose by 14.73% to -$9.6 million in 2023, then slumped by 56.09% to -$15.1 million in 2024, then climbed by 1.97% to -$15.4 million in 2025.
  • Its Cash from Operations stands at -$15.4 million for Q3 2025, versus -$53.0 million for Q2 2025 and -$11.9 million for Q1 2025.